Publications by authors named "C Prelipcean"

Inflammatory bowel disease (IBD) comprises two types of chronic intestinal disorders: Crohn's disease and ulcerative colitis. In long-standing ulcerative colitis disease activity, histological persistent inflammation has been linked to an increased risk of relapse, and long-term corticosteroid use, even when endoscopic remission is reached. In Crohn's disease, the discontinuous nature of lesions and transmural inflammation have limited the standardized histological assessment.

View Article and Find Full Text PDF

Introduction: Peripheral venous access (PVA) is recommended as a first-line vascular approach for therapeutic plasmapheresis with centrifugation methods but not filtration, which usually requires high blood flow. We evaluated the feasibility, efficacy, and safety of double-filtration plasmapheresis (DFPP) with PVA, using ultrasound guidance and regional citrate anticoagulation (RCA), i.e.

View Article and Find Full Text PDF
Article Synopsis
  • Ixekizumab is a biologic treatment targeting the IL-17 pathway, used for conditions like psoriasis and ankylosing spondylitis, alongside Secukinumab and Brodalumab.
  • A case study is presented about a 42-year-old woman who developed severe complications, including bloody diarrhea and fever, just one week after starting Ixekizumab for psoriasis and psoriatic arthritis.
  • Despite attempts at medical treatment, her condition worsened to require emergency colectomy, suggesting that Ixekizumab may be linked to the onset of inflammatory bowel disease.
View Article and Find Full Text PDF

Background: Adapting drug treatments for patients on hemodialysis with multiple chronic pathologies is a complex affair. When prescribing a medication, the risk-benefit analysis usually focuses primarily on the indication of the drug class prescribed. However, the pharmacokinetics of the chosen drug should also be taken into account.

View Article and Find Full Text PDF